NO20013638L - Acetyleniske sulfonamidtiol-TACE-inhibitorer - Google Patents

Acetyleniske sulfonamidtiol-TACE-inhibitorer

Info

Publication number
NO20013638L
NO20013638L NO20013638A NO20013638A NO20013638L NO 20013638 L NO20013638 L NO 20013638L NO 20013638 A NO20013638 A NO 20013638A NO 20013638 A NO20013638 A NO 20013638A NO 20013638 L NO20013638 L NO 20013638L
Authority
NO
Norway
Prior art keywords
tace inhibitors
thiol
acetylenic
acetylenic sulfonamide
sulfonamide thiol
Prior art date
Application number
NO20013638A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013638D0 (no
Inventor
Jeremy Ian Levin
James Ming Chen
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20013638D0 publication Critical patent/NO20013638D0/no
Publication of NO20013638L publication Critical patent/NO20013638L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/50Organo-phosphines
    • C07F9/53Organo-phosphine oxides; Organo-phosphine thioxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
NO20013638A 1999-01-27 2001-07-24 Acetyleniske sulfonamidtiol-TACE-inhibitorer NO20013638L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23839399A 1999-01-27 1999-01-27
PCT/US2000/002143 WO2000044716A1 (en) 1999-01-27 2000-01-27 Acetylenic sulfonamide thiol tace inhibitors

Publications (2)

Publication Number Publication Date
NO20013638D0 NO20013638D0 (no) 2001-07-24
NO20013638L true NO20013638L (no) 2001-07-24

Family

ID=22897697

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013638A NO20013638L (no) 1999-01-27 2001-07-24 Acetyleniske sulfonamidtiol-TACE-inhibitorer

Country Status (21)

Country Link
EP (1) EP1149074B1 (de)
JP (1) JP2002535386A (de)
KR (1) KR20010101691A (de)
CN (1) CN1224612C (de)
AT (1) ATE280152T1 (de)
AU (1) AU766192B2 (de)
BR (1) BR0007727A (de)
CA (1) CA2356480A1 (de)
CZ (1) CZ20012545A3 (de)
DE (1) DE60015079T2 (de)
DK (1) DK1149074T3 (de)
EA (1) EA200100811A1 (de)
ES (1) ES2230064T3 (de)
HK (1) HK1038915A1 (de)
HU (1) HUP0105282A3 (de)
IL (1) IL144347A0 (de)
NO (1) NO20013638L (de)
NZ (1) NZ512306A (de)
PL (1) PL350420A1 (de)
WO (1) WO2000044716A1 (de)
ZA (1) ZA200105069B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033477A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
BR0215182A (pt) 2001-12-20 2004-10-19 Bristol Myers Squibb Co Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003304456A1 (en) 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CA3115038A1 (en) 2018-10-04 2020-04-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL331338A1 (en) * 1996-07-22 1999-07-05 Monsanto Co Thiosulphonamidic metaloprotease inhibitors
DE69719538T2 (de) * 1996-07-22 2004-02-19 Monsanto Co. Thiol-sulfonen als metalloproteinaseinhibitoren

Also Published As

Publication number Publication date
EP1149074A1 (de) 2001-10-31
HK1038915A1 (zh) 2002-04-04
NZ512306A (en) 2003-10-31
WO2000044716A1 (en) 2000-08-03
EA200100811A1 (ru) 2002-12-26
BR0007727A (pt) 2001-10-30
EP1149074B1 (de) 2004-10-20
ES2230064T3 (es) 2005-05-01
ZA200105069B (en) 2002-09-20
IL144347A0 (en) 2002-05-23
KR20010101691A (ko) 2001-11-14
CZ20012545A3 (cs) 2002-04-17
DE60015079D1 (de) 2004-11-25
ATE280152T1 (de) 2004-11-15
PL350420A1 (en) 2002-12-16
DK1149074T3 (da) 2005-01-10
NO20013638D0 (no) 2001-07-24
CN1337947A (zh) 2002-02-27
HUP0105282A2 (hu) 2002-05-29
AU2741700A (en) 2000-08-18
AU766192B2 (en) 2003-10-09
CA2356480A1 (en) 2000-08-03
CN1224612C (zh) 2005-10-26
JP2002535386A (ja) 2002-10-22
DE60015079T2 (de) 2005-03-03
HUP0105282A3 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
WO2000044709A3 (en) ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
DE60015079D1 (de) Acetylenische sulfonamid-thiol-tace-inhibitoren
MY136789A (en) Metalloproteinase inhibitors
DK0934310T3 (da) Thiosyreafledte, monocykliske forbindelser som antikoaguleringsmidler
NZ512446A (en) Alkynyl containing hydroxamic acid compounds as TACE inhibitors
NZ511885A (en) 2,3,4,5-tetrahydro-1H-[1,4]benzodiazephine-3-hydroxamic acid as matrix metalloproteinase inhibitors and as inhibitors of TNF-alpha converting enzyme (TACE)
ATE288922T1 (de) Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
ATE271540T1 (de) Acetylenische arylsulfonamid- und phosphinsäureamid-hydroxamsäure-derivate als tace inhibitoren
MY134437A (en) Process for lowering level of salt required for dilution thickening
DK1109818T3 (da) Phosphoepoxider, fremgangsmåder til deres fremstilling og deres anvendelser
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
EA200100808A1 (ru) ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE
MXPA04004010A (es) Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
EA200100814A1 (ru) Применение ацетиленового орто-сульфонамида и фосфинамидозамещенных бициклических гетероарильных гидроксамовых кислот в качестве ингибиторов tace
EA200100805A1 (ru) Ингибиторы tace на основе гетероарилацетиленсульфонамида и фосфинамида гидроксамовой кислоты
YU18399A (sh) Postupak alkilacije zaštićenih sulfonamida
BR0311590A (pt) Agonistas de brs-3 não-peptìdicos
NO20014845L (no) Anvendelse av arylalkanoylpyridaziner
ATE303390T1 (de) Sulfat von cephemverbindung
DK0691986T3 (da) Hidtil ukendte fremgangsmåder og mellemproduktforbindelser til fremstillingen af blodpladeglycoprotein IIb/IIIa-inhibitorer
IT1317494B1 (it) Procedimento per la produzione di blocchi di schiume pluricomponenti,nonche' impianti per la sua attuazione.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application